Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran First Implementation Strategy in ASCVD
NCT04929249Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2021
- Primary completion
- Sep 2023
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 3 trial of inclisiran in hypercholesterolemia, sponsored by Novartis. Started Jun 2021; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04929249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04929249.